Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma.

Autor: Sánchez Y; Oncology Department, III Congreso Hospital, Pinar del Río 20100, Cuba., Concepción ML; Oncology Department, Camilo Cienfuegos Hospital, Sancti Spíritus 60100, Cuba., Amador Y; Oncology Department, Faustino Pérez Hospital, Matanzas 40100, Cuba., Piriz A; Oncology Department, Agostinho Neto Hospital, Guantánamo 85100, Cuba., Rabassa R; Oncology Department, Manuel Ascunce Domenech Hospital, Camagüey 70100, Cuba., Leyva A; Oncology Department, Vladimir Ilich Lenin Hospital, Holguín 80100, Cuba., Arguelles O; Oncology Department, Antonio Luaces Iraola Hospital, Ciego de Ávila 65200, Cuba., Leblanch L; Oncology Department, Carlos Manuel de Céspedes Hospital, Granma 85100, Cuba., Moret S; Oncology Department, Medical and Surgical Research Center, Havana 11600, Cuba., Rivero G; Oncology Department, Ernesto Guevara de la Serna Hospital, Las Tunas 75100, Cuba., Vasallo AL; Oncology Department, Gustavo Aldereguía Lima Hospital, Cienfuegos 55100, Cuba., Martorell B; Oncology Department, Saturnino Lora Hospital, Santiago de Cuba 90500, Cuba., Guerra PP; Clinical Trial Department, National Coordinating Center of Clinical Trials, Havana 11600, Cuba., Valls AR; Clinical Trial Department, Center of Molecular Immunology, Havana 11600, Cuba., Sánchez L; Clinical Trial Department, Center of Molecular Immunology, Havana 11600, Cuba., Saumell Y; Clinical Trial Department, Center of Molecular Immunology, Havana 11600, Cuba.

Publikováno v: BioMed research international [Biomed Res Int] 2023 Apr 24; Vol. 2023, pp. 1496072. Date of Electronic Publication: 2023 Apr 24 (Print Publication: 2023).